Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results of the ADRIATIC Phase 3 trial of Imfinzi monotherapy and Imfinzi plus Imjudo versus placebo in the treatment of 730 patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT).  The data showed Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo. Related Content: AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical ...